nMARQ Pulmonary Vein Isolation System for the Treatment

Recruiting

1 years - 99 years

All

Phase 3

1 participants needed

1 Location

Brief description of study

Subjects with symptomatic PAF who have had at least one AF episode documented within one (1) year prior to enrollment and who have failed at least one antiarrhythmic drug (AAD). The Main Study will consist of a prospective, multi-center, randomized (1:1 concurrent nMARQ Catheter System [nMARQ] vs THERMOCOOL® Navigational Family of catheters [TC]), controlled, two-arm, single-blind design. Embedded within the Main Study will be a Subpopulation Neurological Assessment (SNA) with a prospective, controlled design, with consecutive enrollment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Atrial Fibrillation, atrial fibrillation
Age: 1 years - 99 years
Gender: All

Updated on 19 Feb 2024. Study ID: 817909

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

nMARQ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

Brief description of study

Eligibility of study

Find a site